Gam-Covid-Vak vaccine ampoule («Sputnik V»). File photoTOKYO, Jan 28 The Japanese medical institution Hibiya Kokusai Clinic officially presented the project for conducting preclinical trials of Russian Sputnik V and Sputnik Light vaccines, noting the «advantages of Russian adenovirus vaccines and recognition of their authority in the international the medical community,” according to the Facebook page of the Russian Embassy in Japan. As noted, the press conference held at the diplomatic mission was attended by Russian Ambassador to Japan Mikhail Galuzin and representatives of the clinic’s management.
"Hibiya Kokusai Clinic management representatives K. Kosaka and A. Suzuki in their speech focused on the advantages of Russian adenovirus vaccines and recognition of their authority in the international medical community, which is confirmed by numerous studies and publications, including in the well-known specialized journal The Lancet", the message notes.
In turn, the Russian Ambassador to Japan «emphasized that such examples of cooperation based on the joint Plan of Cooperation in Eight Priority Areas, agreed between Russian President Vladimir Putin and former Japanese Prime Minister Shinzo Abe, contribute to the development of bilateral ties in the field of healthcare and the strengthening of Russian- Japanese relations in general».
Antibodies after Sputnik V are effective even after six months, scientists said. A press release from the clinic notes that «vaccination with Russian drugs is carried out as part of preclinical trials at the request of patients in order to confirm their effectiveness by doctors.» In addition, the message clarifies that the vaccination will be paid and will not be considered official human vaccination. Satellite V has been approved in 71 countries with a total population of four billion people — more than 50 percent of the world's population. In terms of the number of approvals received by state regulators, this Russian drug ranks second in the world. The vaccine was 97.6 percent effective in an analysis of data from 3.8 million vaccinated Russians — this is higher than the information previously published in the Lancet medical journal (91.6 percent). Data on the use of Sputnik V for vaccination of the population in several countries demonstrate that the development is one of the safest and most effective against coronavirus, RDIF reported. />The Kremlin expressed hope for the early recognition of Sputnik V by WHO